Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 20:14:3335-3349.
doi: 10.2147/OTT.S305098. eCollection 2021.

Functions and Targets of miR-335 in Cancer

Affiliations
Review

Functions and Targets of miR-335 in Cancer

Lingling Ye et al. Onco Targets Ther. .

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs (18~25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also influences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.

Keywords: miR-335 cancer; prognosis; regulation; tumor biology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
MiR-335 regulates cell migration and invasion in cancers through regulating various targets. By targeting RANKL, IGF-IR, ROCK1, BCL-W, Survivin, SHH, LDHB, C-Met, SIX2, OCT4, CPNE1, ICAM-1 and CRKL, miR-186 suppresses cell migration and invasion in cancers.
Figure 2
Figure 2
MiR-335 regulates cell cycle progression in cancers through regulating various targets. MiR-335 inhibits cell cycle progression via targeting CUL4B, MEF2D, CPNE1 and ROCK1. In contrary, miR-335 promotes cell cycle progression by targeting RASA1.
Figure 3
Figure 3
MiR-335 regulates the sensitivity of cancer cells to the anti-cancer treatment. MiR-335 enhances the sensitivity of cancer cells to the anti-cancer treatment via the inhibition of PARP-1, POU5F1, ROCK1, SIAH2, CCNB1, Bcl-W, WBP5, C-Met and CPNE1.
Figure 4
Figure 4
MiR335-related signaling pathways.1, Hedgehog signalling pathway: miR335 inhibites cell growth, and metastasis and drug sensitivity via suppressing Hedgehog pathway. 2, PI3K/AKT/mTOR signaling pathway: miR-335 inhibites cell growth, and metastasis drug sensitivity through suppressing AKT/mTOR signaling pathway. 3. Hippo/YAP signalling pathway: miR335 regulate drug sensitivity and apoptosis through the Hippo pathway.

Similar articles

Cited by

References

    1. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199–227. doi:10.1146/annurev.pathol.4.110807.092222 - DOI - PMC - PubMed
    1. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18:504–511. doi:10.1101/gad.1184404 - DOI - PMC - PubMed
    1. Seitz H. Issues in current microRNA target identification methods. RNA Biol. 2017;14:831–834. doi:10.1080/15476286.2017.1320469 - DOI - PMC - PubMed
    1. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658. doi:10.1053/j.gastro.2007.05.022 - DOI - PMC - PubMed
    1. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012;12:27–33. doi:10.2174/156652412798376170 - DOI - PMC - PubMed